OCT-2026
A monthly round-up of new IBD literature relevant to clinical practice, research and evidence-based care.
This month's harvest circles around a single, unglamorous question: how confidently can we know what is actually happening inside the bowel, and what should we do once we know it? Intestinal ultrasound moves closer to becoming a legitimate treat-to-target endpoint on the strength of a large prospective DACH cohort. A Norwegian randomised trial finally quantifies the price of stopping anti-TNF in ulcerative colitis patients who look, by every available measure, perfectly well. Deep learning is validated for Mayo scoring across three continents and both adults and children. Endoscopic submucosal dissection for dysplasia in IBD is shown to perform comparably in Asian and Western hands — a finding with obvious implications for units building resection capacity outside the traditional East Asian centres. A prebiotic crossover trial reshapes the microbiota without shifting inflammation, a useful corrective to overheated expectations. And a Swedish registry study suggests our surveillance guidelines may be asking the wrong question about family history. Six papers, one theme: better measurement, and honest reckoning with what measurement can and cannot deliver.
Early transmural response on intestinal ultrasound predicts one-year remission - TRUST BEYOND
TRUST BEYOND is a prospective, non-interventional study conducted across 49 sites in Germany, Austria and Switzerland, spanning academic departments and office-based practices. Of 282 patients enrolled with clinically active disease and increased bowel wall thickness, 163 (74 Crohn's disease, 89 ulcerative colitis) completed one year of follow-up on standard-of-care advanced therapy, with clinical, biochemical and sonographic assessment every three months. Transmural response - a ≥25% reduction in bowel wall thickness and/or normalisation to ≤3 mm in the most affected segment - was reached by week 12 in 55.4% of Crohn's and 65.2% of colitis patients, rising to 66.2% and 77.5% by week 52.
Transmural healing, which additionally requires normalised Doppler signal, was substantially harder to achieve (27.0% and 39.3% respectively). The headline finding is predictive: on multivariable analysis correcting for collinearity, transmural response at week 12 was the only independent predictor of clinical remission at week 52 (OR 4.3, 95% CI 2.45–7.52; p<0.001). Response kinetics differed by phenotype — ileal wall thickness continued falling to week 52, while sigmoid thickness in ulcerative colitis plateaued at week 12.
Stopping anti-TNF in deep remission in ulcerative colitis - the BIOSTOP trial
Between 2017 and 2021, 172 patients from 19 Norwegian hospitals — all in deep clinical, biochemical and endoscopic remission on maintenance anti-TNF — were randomised 1:1 to withdrawal or continuation, with a non-inferiority margin of 15%. The trial did not demonstrate non-inferiority. At two years, endoscopically confirmed remission (Mayo endoscopic score 0–1) was present in 80% (66/82) of the withdrawal arm versus 96% (78/81) of those who continued. Flares occurred in 52% (45/86) of patients who stopped, against 12% (10/86) who did not.
The reassuring counterweight is that retreatment worked: anti-TNF was successfully reinstated in 74% (20/27) of those who required it, with recapture of both clinical and endoscopic remission in roughly three of four. A companion transcriptomic analysis of rectal biopsies from the same cohort found that pre-withdrawal mucosal gene expression could not distinguish future relapsers from those who stayed well, though relapse and flare episodes were both marked by inflammatory signatures including CXCL9, CXCL10, OSMR and SELE.
Automated AI-based Mayo endoscopic scoring across adult and paediatric cohorts
Interobserver variability in endoscopic scoring remains one of the softer joints in our treat-to-target architecture, and AI has been proposed as the fix for years without much external validation. This group trained convolutional neural networks on the LIMUC dataset (564 adults, 11,276 images, Turkey), then tested them on two entirely independent cohorts: Tongji Medical College (308 adults, 7,978 images, China) and the Emory Paediatric Cohort (80 children, 113 images, USA).
Two models were built — UC-Re for binary remission classification (MES 0–1 versus 2–3) and UC-MES for four-class grading. UC-Re achieved AUCs of 0.98, 0.95 and 0.98 across the three datasets, with F1 scores of 0.92, 0.87 and 0.93. UC-MES showed ordinal agreement of QWK 0.81–0.85, approaching inter-expert agreement of 0.88, and most errors fell between adjacent categories — the same mistakes humans make. Performance in the paediatric cohort was comparable to expert gastroenterologists.
Endoscopic submucosal dissection for IBD-associated neoplasia: Asia versus the West
Chronic inflammation produces submucosal fibrosis, and fibrosis is the enemy of clean dissection planes — which is why ESD in colitis-associated dysplasia has remained contentious even as it becomes routine for sporadic lesions. This systematic review and meta-analysis pooled 20 studies covering 565 patients and 732 lesions. En-bloc resection was achieved in 95.7% (95% CI 93.5–97.9), R0 resection in 84.6% (79.4–90.1) and curative resection in 83.9% (76.3–92.4).
Post-procedural bleeding occurred in 7.0% and perforation in 7.9%. Local recurrence was 5.3%, and 13.3% of patients ultimately required additional surgery. Critically, no outcome differed significantly between Asian and Western studies — a departure from the historical East–West gap seen in sporadic colorectal ESD series. The authors are candid that certainty of evidence was low for four outcomes and very low for the remainder, reflecting the observational, largely retrospective source data.
2′-Fucosyllactose in mild-to-moderate ulcerative colitis: a randomised crossover trial
Human milk oligosaccharides are well characterised in infants and barely studied in adults. This trial followed a pre-competitive in vitro screen in which 2′-fucosyllactose (2′-FL), an oligofructose-enriched inulin and a galacto-oligosaccharide mixture were fermented with faecal samples from patients with active ulcerative colitis; 2′-FL best suppressed Desulfovibrio species — sulphate-reducing bacteria long implicated in UC — and produced the greatest acetate rise over 48 hours, so it was taken forward.
Thirty-eight patients with mild-to-moderate ulcerative colitis were randomised in a double-blind, placebo-controlled crossover design to 28 days of 2′-FL or maltodextrin. The microbiota response was clear and selective: enrichment of saccharolytic taxa, dominated by an increase in Bifidobacterium. Global metabolic profiles on principal component analysis did not separate between interventions. Exploratory analysis of faecal short-chain fatty acids stratified by clinical response (≥2-point SCCAI reduction) examined isobutyrate and valerate changes in responders versus non-responders.
Family history and colorectal cancer risk in IBD — rethinking the surveillance question
A Swedish nationwide registry study from Karolinska Institutet linked the Patient Register, Cancer Register, Cause of Death Register, Multigeneration Register and the ESPRESSO cohort to examine how family cancer burden shapes colorectal cancer risk in IBD, using matched general-population comparators. Patients with IBD who had several close relatives with colorectal cancer were significantly more likely to develop it themselves.
Two findings unsettle current practice. First, existing international guidelines pivot largely on whether a first-degree relative developed colorectal cancer before the age of 50; the authors argue the number of affected relatives may be the more informative risk marker. Second, among people with a first-degree relative affected by colorectal cancer, absolute risk was broadly similar whether or not they had IBD — implying that familial burden operates somewhat independently of the inflammation-driven pathway we usually foreground.